Advance your immune-oncology research with Leinco Technologies’ high-quality PD-L1 antibodies, including anti-PD-L1/B7-H1 monoclonal, polyclonal, and recombinant antibodies, to support immune-oncology research. PD-L1 acts as a cancer checkpoint by binding to PD-1 on T-cells, inhibiting their ability to attack and destroy tumor cells. Our catalog features a wide selection of antibodies, including the popular clone 10F.9G2 (Anti-Mouse PD-L1), which is capable of blocking PD-L1 interactions with both PD-1 and B7-1 (CD80).
Leinco’s PD-L1 antibodies are rigorously validated for a wide range of applications, including:
- In vivo Use: in vivo antibodies in mouse studies are used to modulate immune responses, target specific cells or proteins, and evaluate therapeutic efficacy.
- Immunohistochemistry (IHC): Visualize PD-L1 expression in tissue samples.
- Flow Cytometry: Analyze PD-L1 expression in cell populations
- Western Blotting: Detect PD-L1 protein levels.
- Biosimilars: Are used to assess their pharmacokinetic and pharmacodynamic properties, as well as their efficacy and safety, compared to the originator biologic drug.
Furthermore, we provide in vivo GOLD™ antibodies and enhanced versions of our in vivo PLATINUM™ line, which are designed to surpass the stringent requirements of any in vivo study.
